Structural and computational biology of the molecular chaperone Hsp90: From understanding molecular mechanisms to computer-based inhibitor design

Current Topics in Medicinal Chemistry

Volumn 9, Issue 15, 2009, Pages 1369-1385

  Verkhivker, Gennady M ^a,b   Dixit, Anshuman ^a   Morra, Giulia ^c   Colombo, Giorgio ^c  

^a UNIVERSITY OF KANSAS   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c CNR   (Italy)

Author keywords

Allosteric regulation; Computer aided drug design; In silico screening; Inhibitor identification; Molecular docking; Protein dynamics; Signal communication

Indexed keywords

CHAPERONE; HEAT SHOCK PROTEIN 90;

ALLOSTERISM; BINDING SITE; CANCER THERAPY; COMPUTER SYSTEM; CONFORMATION; DRUG DESIGN; DRUG MECHANISM; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN STRUCTURE; REVIEW;

ANIMALS; COMPUTATIONAL BIOLOGY; DRUG DESIGN; HSP90 HEAT-SHOCK PROTEINS; HUMANS; PROTEIN CONFORMATION; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 74249085580     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/156802609789895700     Document Type: Review

References (197)

1. Richter, K.; Buchner, J. Hsp90: chaperoning signal transduction. J. Cell Physiol. 2001, 188, 281-290.
2. Young, J. C.; Moarefi, I.; Hartl, F. U. Hsp90: a specialized but essential protein-folding tool. J. Cell Biol. 2001, 154, 267-273.
3. Picard, D. Heat-shock protein 90, a chaperone for folding and regulation. Cell Mol. Life Sci. 2002, 59, 1640-1648.
4. Pratt, W. B.; Toft, D. O. Regulation of signaling protein function and trafficking by the hsp90/hsp70-based chaperone machinery. Exp. Biol. Med. (Maywood) 2003, 228, 111-133.
5. Young, J. C.; Agashe, V. R.; Siegers, K.; Hartl, U. F. Pathways of chaperone-mediated protein folding in the cytosol. Nat. Rev. Mol. Cell Biol. 2004, 5, 781-791.
6. Whitesell, L.; Lindquist, S. L. Hsp90 and the chaperoning of cancer. Nat. Rev. Cancer 2005, 5, 761-772.
7. Rutherford, S.; Hirate, Y.; Swalla, B. J. The Hsp90 capacitor, developmental remodeling, and evolution: the robustness of gene networks and the curious evolvability of metamorphosis. Crit. Rev. Biochem. Mol. Biol. 2007, 42, 355-372.
8. Neckers, L. Heat shock protein 90: the cancer chaperone. J. Biosci. 2007, 32, 517-530.
9. Pearl, L. H.; Prodromou, C.; Workman, P. The Hsp90 molecular chaperone: an open and shut case for treatment. Biochem. J. 2008, 410, 439-453.
10. Mcclellan, A. J.; Xia, Y.; Deutschbauer, A. M.; Davis, R. W.; Gerstein, M.; Frydman, J. Diverse cellular functions of the Hsp90 molecular chaperone uncovered using systems approaches. Cell 2007, 131, 121-135.
11. Zhao, R.; Davey, M.; Hsu, Y. C.; Kaplanek, P.; Tong, A.; Parsons, A. B.; Krogan, N.; Cagney, G.; Mai, D.; Greenblatt, J.; Boone, C.; Emili, A.; Houry, W. A. Navigating the chaperone network: an integrative map of physical and genetic interactions mediated by the hsp90 chaperone. Cell 2005, 120, 715-727.
12. Isaacs, J. S.; Xu, W.; Neckers, L. Heat shock protein 90 as a molecular target for cancer therapeutics. Cancer Cell 2003, 3, 213-217.
13. Bagatell, R.; Whitesell, L. Altered Hsp90 function in cancer: a unique therapeutic opportunity. Mol. Cancer Ther. 2004, 3, 1021-1030.
14. Xu, W.; Neckers, L. Targeting the molecular chaperone heat shock protein 90 provides a multifaceted effect on diverse cell signaling pathways of cancer cells. Clin. Cancer Res. 2007, 13, 1625-1629.
15. Neckers, L.; Ivy, P. S. Heat shock protein 90. Curr. Opin. Oncol. 2003, 15, 419-424.
16. Workman, P. Overview: translating Hsp90 biology into Hsp90 drugs. Curr. Cancer Drug Targets 2003, 3, 297-300.
17. Mcdonald, E.; Workman, P.; Jones, K. Inhibitors of the HSP90 molecular chaperone: attacking the master regulator in cancer. Curr. Top. Med. Chem. 2006, 6, 1091-1107.
18. Workman, P.; de Billy, E. Putting the heat on cancer. Nat. Med. 2007, 13, 1415-1417.
19. Sharp, S.; Workman, P. Inhibitors of the HSP90 molecular chaperone: current status. Adv. Cancer Res. 2006, 95, 323-348.
20. Powers, M. V.; Workman, P. Inhibitors of the heat shock response: biology and pharmacology. FEBS Lett. 2007, 581, 3758-3769.
21. Workman, P.; Burrows, F.; Neckers, L.; Rosen, N. Drugging the cancer chaperone HSP90: combinatorial therapeutic exploitation of oncogene addiction and tumor stress. Ann. N. Y. Acad. Sci. 2007, 1113, 202-216.
22. Chadli, A.; Bouhouche, I.; Sullivan, W.; Stensgard, B.; Mcmahon, N.; Catelli, M. G.; Toft, D. O. Dimerization and N-terminal domain proximity underlie the function of the molecular chaperone heat shock protein 90. Proc. Natl. Acad. Sci. USA 2000, 97, 12524-12529.
23. Prodromou, C.; Panaretou, B.; Chohan, S.; Siligardi, G.; O'Brien, R.; Ladbury, J. E.; Roe, S. M.; Piper, P. W.; Pearl, L. H. The ATPase cycle of Hsp90 drives a molecular 'clamp' via transient dimerization of the N-terminal domains. EMBO J. 2000, 19, 4383-4392.
24. Meyer, P.; Prodromou, C.; Hu, B.; Vaughan, C.; Roe, M. S.; Panaretou, B.; Piper, P. W.; Pearl, L. H. Structural and functional analysis of the middle segment of hsp90: implications for ATP hydrolysis and client protein and cochaperone interactions. Mol. Cell 2003, 11, 647-658.
25. Pearl, L. H.; Prodromou, C. Structure and mechanism of the Hsp90 molecular chaperone machinery. Annu. Rev. Biochem. 2006, 75, 271-294.
26. Prodromou, C.; Roe, S. M.; Piper, P. W.; Pearl, L. H. A molecular clamp in the crystal structure of the N-terminal domain of the yeast Hsp90 chaperone. Nat. Struct. Biol. 1997, 4, 477-482.
27. Prodromou, C.; Roe, S. M.; O'Brien, R.; Ladbury, J. E.; Piper, P. W.; Pearl, L. H. Identification and structural characterization of the ATP/ADP-binding site in the Hsp90 molecular chaperone. Cell 1997, 90, 65-75.
28. Huai, Q.; Wang, H.; Liu, Y.; Kim, H. Y.; Toft, D.; Ke, H. Structures of the N-terminal and middle domains of E. coli Hsp90 and conformation changes upon ADP binding. Structure 2005, 13, 579-590.
29. Hawle, P.; Siepmann, M.; Harst, A.; Siderius, M.; Reusch, P. H.; Obermann, W. M. J. The middle domain of Hsp90 acts as a discriminator between different types of client proteins. Mol. Cell Biol . 2006, 26, 8385-8395.
30. Immormino, R. M.; Dollins, E. D.; Shaffer, P. L.; Soldano, K. L.; Walker, M. A.; Gewirth, D. T. Ligand-induced conformational shift in the N-terminal domain of GRP94, an Hsp90 chaperone. J. Biol. Chem. 2004, 279, 46162-46171.
31. Dollins, E. D.; Immormino, R. M.; Gewirth, D. T. Structure of unliganded GRP94, the endoplasmic reticulum Hsp90. Basis for nucleotide-induced conformational change J. Biol. Chem. 2005, 280, 30438-30447.
32. Harris, S. F.; Shiau, A. K.; Agard, D. A. The crystal structure of the carboxy-terminal dimerization domain of htpG, the Escherichia coli Hsp90, reveals a potential substrate binding site. Structure 2004, 12, 1087-1097.
33. Ali, M.M. U.; Roe, M. S.; Vaughan, C. K.; Meyer, P.; Panaretou, B.; Piper P.W.; Prodromou, C.; Pearl, L. H. Crystal structure of an Hsp90-nucleotide-p23/ Sba1 closed chaperone complex. Nature 2006, 440, 1013-1017.
34. Shiau, A. K.; Harris, S. F.; Southworth, D. R.; Agard, D. A. Structural Analysis of E. coli hsp90 reveals dramatic nucleotide-dependent conformational rearrangements. Cell 2006, 127, 329-340.
35. Dollins, E. D.; Warren, J. J.; Immormino, R. M.; Gewirth, D. T. Structures of GRP94-nucleotide complexes reveal mechanistic differences between the hsp90 chaperones. Mol. Cell 2007, 28, 41-56.
36. Vaughan, C. K.; Gohlke, U.; Sobott, F.; Good, V. M.; Ali, M.M. U.; Prodromou, C.; Robinson, C. V.; Saibil, H. R.; Pearl, L. H. Structure of an Hsp90-Cdc37-Cdk4 complex. Mol. Cell 2006, 23, 697-707.
37. Richter, K.; Soroka, J.; Skalniak, L.; Leskovar, A.; Hessling, M.; Reinstein, J.; Buchner, J. Conserved conformational changes in the ATPase cycle of human Hsp90. J. Biol. Chem. 2008, 283, 17757-17765.
38. Zhang, W.; Hirshberg, M.; Mclaughlin, S. H.; Lazar, G. A.; Grossmann, G. J.; Nielsen, P. R.; Sobott, F.; Robinson, C. V.; Jackson, S. E.; Laue, E. D. Biochemical and structural studies of the interaction of Cdc37 with Hsp90. J. Mol. Biol. 2004, 340, 891-907.
39. Cunningham, C. N.; Krukenberg, K. A.; Agard, D. A. Intra- and intermonomer interactions are required to synergistically facilitate ATP hydrolysis in Hsp90. J. Biol. Chem. 2008, 283, 21170-21178.
40. Krukenberg, K. A.; Forster, F.; Rice, L. M.; Sali, A.; Agard, D. A. Multiple conformations of E. coli Hsp90 in solution: insights into the conformational dynamics of Hsp90. Structure 2008, 16, 755-765.
41. Bron, P.; Giudice, E.; Rolland, J. P.; Buey, R. M.; Barbier, P.; Diaz, F. J.; Peyrot, V.; Thomas, D.; Garnier, C. Apo-Hsp90 coexists in two open conformational states in solution. Biol. Cell 2008, 100, 413-4525.
42. Krukenberg, K. A.; Böttcher, U.M., Southworth, D. R.; Agard, D. A. Grp94, the endoplasmic reticulum Hsp90, has a similar solution conformation to cytosolic Hsp90 in the absence of nucleotide. Protein Sci. 2009, 18(9), 1815-1827.
43. Vaughan, C. K.; Piper, P. W.; Pearl, L. H.; Prodromou, C. A common conformationally coupled ATPase mechanism for yeast and human cytoplasmic Hsp90s. FEBS J. 2009, 276, 199-209.
44. Southworth, D. R.; Agard, D. A. Species-dependent ensembles of conserved conformational States define the Hsp90 chaperone ATPase cycle Mol. Cell 2008, 32, 631-640.
45. Phillips, J. J.; Yao, Z. P.; Zhang, W.; Mclaughlin, S.; Laue, E. D.; Robinson, C.V., Jackson, S. E. Conformational dynamics J. Mol. Biol. 2007, 372, 1189-1203.
46. Frey, S.; Leskovar, A.; Reinstein, J.; Buchner, J. The ATPase cycle of the endoplasmic chaperone Grp94. J. Biol. Chem. 2007, 282, 35612-35620.
47. Krukenberg, K. A.; Southworth, D. R.; Street, T. O.; Agard, D. A. pH-dependent conformational changes in bacterial Hsp90 reveal a Grp94-like conformation at pH 6 that is highly active in suppression of citrate synthase aggregation. J. Mol. Biol. 2009, 390, 278-291.
48. Hawle, P.; Siepmann, M.; Harst, A.; Siderius, M.; Reusch, P. H.; Obermann, W. M. J. The middle domain of Hsp90 acts as a discriminator between different types of client proteins. Mol. Cell Biol. 2006, 26, 8385-8395.
49. Roe, M. S.; Ali, M.M. U.; Meyer, P.; Vaughan, C. K.; Panaretou, B.; Piper, P.W.; Prodromou, C.; Pearl, L. H. The Mechanism of Hsp90 regulation by the protein kinase-specific cochaperone p50(cdc37). Cell 2004, 116, 87-98.
50. Meyer, P.; Prodromou, C.; Liao, C.; Hu, B.; Roe, M. S.; Vaughan, C. K.; Vlasic, I.; Panaretou, B.; Piper, P. W.; Pearl, L. H. Structural basis for recruitment of the ATPase activator Aha1 to the Hsp90 chaperone machinery. EMBO J. 2004, 23, 511-519.
51. Siligardi, G.; Hu, B.; Panaretou, B.; Piper, P. W.; Pearl, L. H.; Prodromou, C. Co-chaperone regulation of conformational switching in the Hsp90 ATPase cycle. J. Biol. Chem. 2004, 279, 51989-51998.
52. Richter, K.; Walter, S.; Buchner, J. The Co-chaperone Sba1 connects the ATPase reaction of Hsp90 to the progression of the chaperone cycle. J. Mol. Biol. 2004, 342, 1403-1413.
53. Mclaughlin, S. H.; Sobott, F.; Yao, Z. P.; Zhang, W.; Nielsen, P. R.; Grossmann, G.J.; Laue, E. D.; Robinson, C. V.; Jackson, S. E. The co-chaperone p23 arrests the Hsp90 ATPase cycle to trap client proteins. J. Mol. Biol. 2006, 356, 746-758.
54. Onuoha, S. C.; Coulstock, E. T.; Grossmann, J. G.; Jackson, S. E. Structural studies on the co-chaperone Hop and its complexes with Hsp90. J. Mol. Biol. 2008, 379, 732-744.
55. Flom, G.; Behal, R. H.; Rosen, L.; Cole, D. G.; Johnson, J. L. Definition of the minimal fragments of Sti1 required for dimerization, interaction with Hsp70 and Hsp90 and in vivo functions. Biochem J. 2007, 404, 159-167.
56. Prodromou, C.; Siligardi, G.; O'Brien, R.; Woolfson, D. N.; Regan, L.; Panaretou, B.; Ladbury, J. E.; Piper, P. W.; Pearl, L. H. Regulation of Hsp90 ATPase activity by tetratricopeptide repeat (TPR)-domain co-chaperones. EMBO J. 1999, 18, 754-762.
57. Panaretou, B.; Siligardi, G.; Meyer, P.; Maloney, A.; Sullivan, J. K.; Singh, S.; Millson, S. H.; Clarke, P. A.; Hansen, S. N.; Stein, R.; Cramer, R.; Mollapour, M.; Workman, P.; Piper, P. W.; Pearl, L. H.; Prodromou, C. Activation of the ATPase activity of hsp90 by the stress-regulated cochaperone aha1. Mol. Cell 2002, 10, 1307-1318.
58. Johnson, J. L.; Halas, A.; Flom, G. Nucleotide-dependent interaction of Saccharomyces cerevisiae Hsp90 with the cochaperone proteins Sti1, Cpr6, and Sba1. Mol. Cell Biol. 2007, 27, 768-76.
59. Pearl, L. H. Hsp90 and Cdc37 - a chaperone cancer conspiracy. Curr. Opin. Genet. Dev. 2005, 15, 55-61.
60. Caplan, A. J.; Mandal, A. K.; Theodoraki, M. A. Molecular chaperones and protein kinase quality control. Trends Cell Biol. 2007, 17, 87-92.
61. Karnitz, L. M.; Felts, S. J. Cdc37 regulation of the kinome: when to hold 'em and when to fold 'em. Sci. STKE 2007, 385.
62. Koga, F.; Xu, W.; Karpova, T. S.; Mcnally, J. G.; Baron, R.; Neckers, L. Hsp90 inhibition transiently activates Src kinase and promotes Src-dependent Akt and Erk activation. Proc. Natl. Acad. Sci. USA 2006, 103, 11318-22.
63. Xu, W.; Yuan, X.; Beebe, K.; Xiang, Z.; Neckers, L. Loss of Hsp90 association up-regulates Src-dependent ErbB2 activity. Mol. Cell Biol. 2007, 27, 220-228.
64. Hinz, M.; Broemer, M.; Arslan, S. C.; Otto, A.; Mueller, E. C.; Dettmer, R.; Scheidereit, C. Signal responsiveness of IkappaB kinases is determined by Cdc37-assisted transient interaction with Hsp90. J. Biol. Chem .2007, 282, 32311-32319.
65. Wrighton, K. H.; Lin, X.; Feng, X. H. Critical regulation of TGFbeta signaling by Hsp90. Proc. Natl. Acad. Sci. USA 2008, 105, 9244-9249.
66. Rodina, A.; Vilenchik, M.; Moulick, K.; Aguirre, J.; Kim, J.; Chiang, A.; Litz, J.; Clement, C. C.; Kang, Y.; She, Y.; Wu, N.; Felts, S.; Wipf, P.; Massague, J.; Jiang, X.; Brodsky, J. L.; Krystal, G. W.; Chiosis, G. Selective compounds define Hsp90 as a major inhibitor of apoptosis in small-cell lung cancer. Nat. Chem. Biol. 2007, 3, 498-507.
67. Shimamura, T.; Li, D.; Ji, H.; Haringsma, H. J.; Liniker, E.; Borgman, C. L.; Lowell, A. M.; Minami, Y.; Mcnamara, K.; Perera, S. A.; Zaghlul, S.; Thomas, R. K.; Greulich, H.; Kobayashi, S.; Chirieac, L. R.; Padera, R. F.; Kubo, S.; Takahashi, M.; Tenen, D. G.; Meyerson, M.; Wong, K. K.; Shapiro, G. I. Hsp90 inhibition suppresses mutant EGFR-T790M signaling and overcomes kinase inhibitor resistance. Cancer Res. 2008, 68, 5827-5838.
68. Miyata, Y.; Yahara, I. The 90-kDa heat shock protein, HSP90, binds and protects casein kinase II from self-aggregation and enhances its kinase activity. J. Biol. Chem. 1992, 267, 7042-7047.
69. Miyata, Y.; Yahara, I. Interaction between casein kinase II and the 90-kDa stress protein, HSP90. Biochemistry 1995, 34, 8123-8129.
70. Fujita, N.; Sato, S.; Ishida, A.; Tsuruo, T. Involvement of Hsp90 in signaling and stability of 3-phosphoinositide-dependent kinase-1. J. Biol. Chem. 2002, 277, 10346-10353.
71. Sato, S.; Fujita, N.; Tsuruo, T. Modulation of Akt kinase activity by binding to Hsp90. Proc. Natl. Acad. Sci. USA 2000, 97, 10832-10837.
72. Scroggins, B. T.; Prince, T.; Shao, J.; Uma, S.; Huang, W.; Guo, Y.; Yun, B.G.; Hedman, K.; Matts, R. L.; Hartson, S. D. High affinity binding of Hsp90 is triggered by multiple discrete segments of its kinase clients. Biochemistry 2003, 42, 12550-12561.
73. Xu, W.; Yuan, X.; Xiang, Z.; Mimnaugh, E.; Marcu, M.; Neckers, L. Surface charge and hydrophobicity determine ErbB2 binding to the Hsp90 chaperone complex. Nat. Struct. Mol. Biol. 2005, 12, 120-126.
74. Prince, T.; Matts, R. L. Definition of protein kinase sequence motifs that trigger high affinity binding of Hsp90 and Cdc37. J. Biol. Chem. 2004, 279, 39975-39981.
75. Zhao, Q.; Boschelli, F.; Caplan, A. J.; Arndt, K. T. Identification of a conserved sequence motif that promotes Cdc37 and cyclin D1 binding to Cdk4. J. Biol. Chem. 2004, 279, 12560-12564.
76. Citri, A.; Harari, D.; Shohat, G.; Ramakrishnan, P.; Gan, J.; Lavi, S.; Eisenstein, M.; Kimchi, A.; Wallach, D.; Pietrokovski, S.; Yarden, Y. Hsp90 recognizes a common surface on client kinases. J. Biol. Chem. 2006, 281, 14361-14369.
77. Vaughan, C. K.; Mollapour, M.; Smith, J. R.; Truman, A.; Hu, B.; Good, V. M.; Panaretou, B.; Neckers, L.; Clarke, P. A.; Workman, P.; Piper, P. W.; Prodromou, C.; Pearl, L. H. Hsp90-dependent activation of protein kinases is regulated by chaperone-targeted dephosphorylation of Cdc37. Mol. Cell 2008, 31, 886-895.
78. Sreeramulu, S.; Jonker, H. R. A.; Langer, T.; Richter, C.; Roy,; Schwalbe, H. The human Cdc37.Hsp90 complex studied by heteronuclear NMR spectroscopy. J. Biol. Chem. 2009, 284, 3885-3896.
79. Gould, C. M.; Kannan, N.; Taylor, S. S.; Newton, A. C. The chaperones Hsp90 and Cdc37 mediate the maturation and stabilization of protein kinase C through a conserved PXXP motif in the C-terminal tail. J. Biol. Chem. 2009, 284, 4921-4935.
80. Pratt, W. B.; Morishima, Y.; Osawa, Y. The Hsp90 chaperone machinery regulates signaling by modulating ligand binding clefts. J. Biol. Chem. 2008, 283, 22885-22889.
81. Zhang, M.; Boter, M.; Li, K.; Kadota, Y.; Panaretou, B.; Prodromou, C.; Shirasu, K.; Pearl, L. H. Structural and functional coupling of Hsp90- and Sgt1-centred multi-protein complexes. EMBO J. 2008, 27, 2789-2798.
82. Colombo, G.; Morra, G.; Meli, M.; Verkhivker, G. Understanding ligand-based modulation of the Hsp90 molecular chaperone dynamics at atomic resolution. Proc. Natl. Acad. Sci. USA 2008, 105, 7976-7981.
83. Morra, G.; Verkhivker, G.; Colombo, G. Modeling signal propagation mechanisms and ligand-based conformational dynamics of the Hsp90 molecular chaperone full-length dimer. PLoS Comput. Biol . 2009, 5, e1000323.
84. Ho, B. K.; Agard, D. A. Probing the flexibility of large conformational changes in protein structures through local perturbations. PLoS Comput. Biol. 2009, 5, e1000343.
85. Kumar, S.; Ma, B.; Tsai, C. J.; Sinha, N.; Nussinov, R. Folding and binding cascades: dynamic landscapes and population shifts. Protein Sci. 2000, 9, 10-19.
86. Levy, Y.; Wolynes, P. G.; Onuchic, J. N. Protein folding topology determines binding mechanism. Proc. Natl.Acad. Sci. USA 2004, 101, 511-516.
87. Verkhivker, G. M.; Bouzida, D.; Gehlhaar, D. K.; Rejto, P. A.; Freer, S.T.; Rose, P.W. Complexity and simplicity of ligand-macromolecule interactions : the energy landscape perspective. Curr. Opin. Struct. Biol. 2002, 12, 197-203.
88. Verkhivker, G. M.; Bouzida, D.; Gehlhaar, D. K.; Rejto, P. A.; Freer , S.T.; Rose, P. W. Simulating disorder - order transitions in molecular recognition of unstructured proteins : where folding meets binding. Proc. Natl. Acad. Sci. USA 2003, 100, 5148-5153.
89. Wang, J.; Verkhivker, G. M. Energy landscape theory, funnels, specificity, and optimal criterion of biomolecular binding. Phys. Rev. Lett. 2003, 90, 188101.
90. Wang, J.; Zheng, X.; Yang, Y.; Drueckhammer, D.; Yang, W.; Verkhivker, G. Wang, E. Quantifying intrinsic specificity: A potential complement to affinity in drug screening. Phys. Rev. Lett. 2007, 99, 198101.
91. Frauenfelder, H.; Sligar, S. G.; Wolynes, P. G. The energy landscapes and motions of proteins Science 1991, 254, 1598-1603.
92. Frauenfelder, H.; Mcmahon, B. H.; Fenimore, P. W. Myoglobin: the hydrogen atom of biology and a paradigm of complexity. Proc. Natl. Acad. Sci. USA 2003, 100, 8615-8617.
93. Katherine,; Thai, V.; Lei, M.; Ott, M.; Watz, M. W.; Fenn, T.; Pozharski, E.; Wilson, M. A.; Petsko, G. A.; Karplus, M.; Hubner, C. G.; Kern, D. Intrinsic motions along an enzymatic reaction trajectory. Nature 2007, 450, 838-844.
94. Katherine,; Lei, M.; Thai, V.; Kerns, J. S.; Karplus, M.; Kern, D. A hierarchy of timescales in protein dynamics is linked to enzyme catalysis. Nature 2007, 450, 913-916.
95. Lange, O. F.; Lakomek, N. A.; Fares, C.; Schroder, G. F.; Walter, K. F.A.; Becker, S.; Meiler, J.; Grubmuller, H.; Griesinger, C.; de Groot, B. L. Recognition dynamics up to microseconds revealed from an RDC-derived ubiquitin ensemble in solution Science 2008, 320, 1471-1475.
96. Eisenmesser, E. Z.; Millet, O.; Labeikovsky, W.; Korzhnev, D. M.; Watz, M.W.; Bosco, D. A.; Skalicky, J. J.; Kay, L. E.; Kern, D. Intrinsic dynamics of an enzyme underlies catalysis. Nature 2005, 438, 117-121.
97. Tang, C.; Schwieters, C. D.; Clore, M. G. Open-to-closed transition inapo maltose-binding protein observed by paramagnetic NMR. Nature 2007, 449, 1078-1082.
98. James, L. C.; Roversi, P.; Tawfik, D. S. Antibody multispecificity mediated by conformational diversity. Science 2003, 299, 1362-1367.
99. Hanahan, D.; Weinberg, R. A. The hallmarks of cancer. Cell 2000, 100, 57-70.
100. Maloney, A.; Clarke, P. A.; Workman, P. Genes and proteins governing the cellular sensitivity to HSP90 inhibitors: a mechanistic perspective. Curr. Cancer Drug Targets 2003, 3, 331-341.
101. Weinstein, B. I. Addiction to oncogenes-the Achilles heal of cancer. Science 2002, 297, 63-64.
102. Sharma, S. V.; Settleman, J. Oncogene addiction: setting the stage for molecularly targeted cancer therapy. Genes Dev. 2007, 21, 3214-3231.
103. Chiosis, G. Targeting chaperones in transformed systems-a focus on Hsp90 and cancer. Expert Opin. Ther. Targets 2006, 10, 37-50.
104. Banerji, U. Heat shock protein 90 as a drug target: some like it hot. Clin. Cancer Res. 2009, 15, 9-14.
105. Chiosis, G.; Lopes, E. C.; Solit, D. Heat shock protein-90 inhibitors: a chronicle from geldanamycin to today's agents. Curr. Opin. Investig. Drugs 2006, 7, 534-541.
106. Kamal, A.; Thao, L.; Sensintaffar, J.; Zhang, L.; Boehm, M. F.; Fritz, L.C.; Burrows, F. J. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 2003, 425, 407-410.
107. Kamal, A.; Boehm, M. F.; Burrows, F. J. Therapeutic and diagnostic implications of Hsp90 activation. Trends Mol. Med. 2004, 10, 283-290.
108. Uehara, Y. Natural product origins of Hsp90 inhibitors. Curr. Cancer Drug Targets 2003, 3, 325-330.
109. Whitesell, L.; Mimnaugh, E. G.; De Costa, B.; Myers, C. E.; Neckers, L. M. Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation. Proc. Natl. Acad. Sci. USA 1994, 91, 8324-8.
110. Smith, D. F.; Whitesell, L.; Nair, S. C.; Chen, S.; Prapapanich, V.; Rimerman, R.A.; Progesterone receptor structure and function altered by geldanamycin, an hsp90-binding agent. Mol. Cell Biol. 1995, 15, 6804-6812.
111. Sharma, S. V.; Agatsuma, T.; Nakano, H. argeting of the protein chaperone, Hsp90, by the transformation suppressing agent, radicicol. Oncogene 1998, 16, 2639-2645.
112. Grenert, J. P.; Sullivan, W. P.; Fadden, P.; Haystead, T. A.; Clark, J.; Mimnaugh, E.; Krutzsch, H.; Ochel, H. J.; Schulte, T.W.; Sausvilee, E.; Neckers, L.M.; Toft, D.O. The amino-terminal domain of heat shock protein 90 (hsp90) that binds geldanamycin is an ATP/ADP switch domain that regulates hsp90 conformation. J. Biol. Chem. 1997, 272, 23843-23850.
113. Roe, S. M.; Prodromou, C.; O'Brien, R.; Ladbury, J. E.; Piper, P. W.; Pearl, L. H. Piper, P. W.; Pearl, L. H. Structural basis for inhibition of the Hsp90 molecular chaperone by the antitumor antibiotics radicicol and geldanamycin. J. Med. Chem. 1999, 42, 260-266.
114. Stebbins, C. E.; Russo, A. A.; Schneider, C.; Rosen, N.; Hartl, F.U.; Pavletich, N. P. Crystal structure of an Hsp90-geldanamycin complex: targeting of a protein chaperone by an antitumor agent. Cell 1997, 89, 239-250.
115. Chiosis, G.; Huezo, H.; Rosen, N.; Mimnaugh, E.; Whitesell, L.; Neckers, L. 17AAG: low target binding affinity and potent cell activity-finding an explanation. Mol. Cancer Ther. 2003, 2, 123-129.
116. Workman, P. Auditing the pharmacological accounts for Hsp90 molecular chaperone inhibitors: unfolding the relationship between pharmacokinetics and pharmacodynamics. Mol. Cancer Ther. 2003, 2, 131-138.
117. Hostein, I.; Robertson, D.; Distefano, F.; Workman, P.; Clarke, P. A. Inhibition of signal transduction by the Hsp90 inhibitor 17-allylamino-17- demethoxygeldanamycin results in cytostasis and apoptosis. Cancer Res. 2001, 61, 4003-4009.
118. Solit, D. B.; Ivy, P. S.; Kopil, C.; Sikorski, R.; Morris, M. J.; Slovin, S.F.; Kelly, K. W.; Delacruz, A.; Curley, T.; Heller, G.; Larson, S.; Schwartz, L.; Egorin, M. J.; Rosen, N.; Scher, H. I. Phase I trial of 17-allylamino-17 demethoxygeldanamycin in patients with advanced cancer. Clin. Cancer Res. 2007, 13, 1775-1782.
119. Kaur, G.; Belotti, D.; Burger, A. M.; Nielson, K. F.; Borsotti, P.; Riccardi, E.; Thillainathan, J.; Hollingshead, M.; Sausville, E. A.; Giavazzi, R. Antiangiogenic properties of 17-(dimethylaminoethylamino)-17- demethoxygeldanamycin: an orally bioavailable heat shock protein 90 modulator. Clin. Cancer Res. 2004, 10, 4813-4821.
120. Smith, V.; Sausville, E. A.; Camalier, R. F.; Fiebig, H. H.; Burger, A. M. Comparison of 17 dimethylaminoethylamino-17-demethoxygeldanamycin (17DMAG) and 17-allylamino-17-demethoxygeldanamycin (17AAG) in vitro: effects on Hsp90 and client proteins in melanoma models. Cancer Chemother. Pharmacol. 2005, 56, 126-137.
121. Ge, J.; Normant, E.; Porter, J. R.; Ali, J. A.; Dembski, M. S.; Gao, Y.; Georges, A. T.; Grenier, L.; Pak, R. H.; Patterson, J.; Sydor, J. R.; Tibbitts, T. T.; Tong, J. K.; Adams, J.; Palombella, V. J. Design, synthesis, and biological evaluation of hydroquinone derivatives of 17-amino-17- demethoxygeldanamycin as potent, water-soluble inhibitors of Hsp90. J. Med. Chem. 2006, 49, 4606-4615.
122. Sydor, J. R.; Normant, E.; Pien, C. S.; Porter, J. R.; Ge, J.; Grenier, L.; Pak, R. H.; Ali, J. A.; Dembski, M. S.; Hudak, J.; Patterson, J.; Penders, C.; Pink, M.; Read, M. A.; Sang, J.; Woodward, C.; Zhang, Y.; Grayzel, D. S.; Wright, J.; Barrett, J. A.; Palombella, V. J.; Adams, J.; Tong, J. K. Development of 17-allylamino-17 demethoxy-geldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90. Proc. Natl. Acad. Sci. USA 2006, 103, 17408-17413.
123. Jez, J. M.; Chen, J. C. H.; Rastelli, G.; Stroud, R. M.; Santi, D. V. Crystal structure and molecular modeling of 17-DMAG in complex with human Hsp90. Chem. Biol.2003, 10, 361-368.
124. Tian, Z. Q.; Liu, Y.; Zhang, D.; Wang, Z.; Dong, S. D.; Carreras, C.W.; Zhou, Y.; Rastelli, G.; Santi, D. V.; Myles, D. C. Synthesis and biological activities of novel 17-aminogeldanamycin derivatives. Bioorg. Med. Chem. 2004, 12, 5317-5329.
125. Rastelli, G.; Tian, Z. Q.; Wang, Z.; Myles, D.; Liu, Y. Structure-based design of 7-carbamate analogs of geldanamycin. Bioorg. Med. Chem. Lett. 2005, 15, 5016-5021.
126. van Montfort, R. L. M.; Workman, P. Structure-based design of molecular cancer therapeutics. Trends Biotechnol. 2009, 27, 315-228.
127. Chiosis, G.; Timaul, M. N.; Lucas, B.; Munster, P. N.; Zheng, F.F.; Lorenzino, S.L.; Rosen, N. A small molecule designed to bind to the adenine nucleotide pocket of Hsp90 causes Her2 degradation and the growth arrest and differentiation of breast cancer cells. Chem. Biol. 2001, 8, 289-299.
128. Vilenchik, M.; Solit, D.; Basso, A.; Huezo, H.; Lucas, B.; He, H.; Rosen N.; Spampinato, C.; Modrich, P.; Chiosis, G. Targeting wide-range oncogenic transformation via PU24FCl, a specific inhibitor of tumor Hsp90. Chem. Biol. 2004, 11, 787-797.
129. Wright, L.; Barril, X.; Dymock, B.; Sheridan, L.; Surgenor, A.; Beswick, M.; Drysdale, M.; Collier, A.; Massey, A.; Davies, N.; Fink, A.; Fromont, C.; Aherne, W.; Boxall, K.; Sharp, S.; Workman, P.; Hubbard, R. E. Structure-activity relationships in purine-based inhibitor binding to Hsp90 isoforms. Chem. Biol. 2004, 11, 775-785.
130. Cheung, K.M.J. Matthews, T. P.; James, K.; Rowlands, M. G.; Boxall, K. J.; Sharp, S. Y.; Maloney, A.; Roe, M. S.; Prodromou, C.; Pearl, L. H.; Aherne, W. G.; Mcdonald, E.; Workman, P. The identification, synthesis, protein crystal structure and in vitro biochemical evaluation of a new 3,4-diarylpyrazole class of Hsp90 inhibitors Bioorg. Med. Chem. Lett. 2005, 15, 3338-3343.
131. Dymock, B. W.; Barril, X.; Brough, P. A.; Cansfield, J. E.; Massey, A.; Mcdonald, E.; Hubbard, R. E.; Surgenor, A.; Massey, A.; Roughley, S. D.; Webb, P.; Workman, P.; Wright, L.; Drysdale, M. J. Novel, potent small-molecule inhibitors of the molecular chaperone Hsp90 discovered through structure-based design. J. Med. Chem. 2005, 48, 4212-4215.
132. Sharp, S. Y.; Prodromou, C.; Boxall, K.; Powers, M. V.; Holmes, J. L.; Box, G.; Matthews, T. P.; Ming, K.; Kalusa, A.; James, K.; Hayes, A.; Hardcastle, A.; Dymock, B., Brough, P. A., Barril, X., Cansfield, J. E., Wright, L., Surgenor, A., Foloppe, N.; Hubbard, R. E.; Aherne, W.; Pearl, L.; Jones, K.; Mcdonald, E.; Raynaud, F.; Eccles, S.; Drysdale, M.; Workman, P. Inhibition of the heat shock protein 90 molecular chaperone in vitro and in vivo by novel, synthetic, potent resorcinylic pyrazole/isoxazole amide analogues. Mol. Cancer Ther. 2007, 6, 1198-1211.
133. Brough, P. A.; Aherne, W.; Barril, X.; Borgognoni, J.; Boxall, K.; Cansfield, J. E.; Kwai Collins, I.; Davies, N. G. M.; Drysdale, M. J.; Dymock, B.; Eccles, S. A.; Finch, H.; Fink, A.; Hayes, A.; Howes, R.; Hubbard, R. E.; James, K.; Jordan, A. M.; Lockie, A.; Martins, V.; Massey, A.; Matthews, T. P.; Mcdonald, E.; Northfield, C. J.; Pearl, L. H.; Prodromou, C.; Ray, S.; Raynaud, F. I.; Roughley, S. D.; Sharp, S. Y.; Surgenor, A.; Walmsley, L. D.; Webb, P.; Wood, M.; Workman, P.; Wright, L. 4,5-diarylisoxazole Hsp90 chaperone inhibitors: potential therapeutic agents for the treatment of cancer. J. Med. Chem. 2008, 51, 196-218.
134. Eccles, S. A.; Massey, A.; Raynaud, F. I.; Sharp, S. Y.; Box, G.; Valenti, M.; Patterson, L.; de Haven Brandon, Gowan, S.; Boxall, F.; Aherne, W.; Rowlands, M.; Hayes, A.; Martins, V.; Urban, F.; Boxall, K.; Prodromou, C.; Pearl, L.; James, K.; Matthews, T. P.; Cheung, K. M.; Kalusa, A.; Jones, K.; Mcdonald, E.; Barril, X.; Brough, P. A.; Cansfield, J. E.; Dymock, B.; Drysdale, M. J.; Finch, H.; Howes, R.; Hubbard, R. E.; Surgenor, A.; Webb, P.; Wood, M.; Wright, L.; Workman, P. NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis. Cancer Res. 2008, 68, 2850-2860.
135. Barril, X.; Beswick, M. C.; Collier, A.; Drysdale, M. J.; Dymock, B. W.; Fink, A.; Grant, K.; Howes, R.; Jordan, A. M.; Massey, A.; Surgenor, A.; Wayne, J.; Workman, P.; Wright, L. 4-Amino derivatives of the Hsp90 inhibitor CCT018159. Bioorg. Med. Chem. Lett. 2006, 16, 2543-2548.
136. Dymock, B.; Barril, X.; Beswick, M.; Collier, A.; Davies, N.; Drysdale, M.; Fink, A.; Fromont, C.; Hubbard, R. E.; Massey, A.; Surgenor, A.; Wright, L. Adenine derived inhibitors of the molecular chaperone HSP90-SAR explained through multiple Xray structures. Bioorg. Med. Chem. Lett. 2004, 14, 32532-8.
137. Park, H.; Kim, Y. J.; Hahn, J. S. A novel class of Hsp90 inhibitors isolated by structure-based virtual screening. Bioorg. Med. Chem. Lett. 2007, 17, 6345-6349.
138. Barril, X.; Brough, P.; Drysdale, M.; Hubbard, R. E.; Massey, A.; Surgenor, A.; Wright, L. Structure-based discovery of a new class of Hsp90 inhibitors. Bioorg. Med. Chem. Lett. 2005, 15, 5187-5191.
139. Huth, J. R.; Park, C.; Petros, A. M.; Kunzer, A. R.; Wendt, M. D.; Wang, X.; Lynch, C. L.; Mack, J. C.; Swift, K. M.; Judge, R. A.; Chen, J.; Richardson, P. L.; Jin, S.; Tahir, S. K.; Matayoshi, E. D.; Dorwin, S. A.; Ladror, U. S.; Severin, J. M.; Walter, K. A.; Bartley, D. M.; Fesik, S. W.; Elmore, S. W.; Hajduk, P. J. Discovery and design of novel HSP90 inhibitors using multiple fragment-based design strategies. Chem. Biol. Drug Des. 2007, 70, 1-12.
140. Kreusch, A.; Han, S.; Brinker, A.; Zhou, V.; Choi, H. S.; He, Y.; Lesley, S.A.; Caldwell, J.; Gu, X. J. Crystal structures of human HSP90alpha-complexed with dihydroxyphenylpyrazoles. Bioorg. Med. Chem. Lett. 2005, 15, 1475-1478.
141. Immormino, R. M.; Kang, Y.; Chiosis, G.; Gewirth, D. T. Structural and quantum chemical studies of 8-aryl-sulfanyl adenine class Hsp90 inhibitors. J. Med. Chem. 2006, 49, 4953-6490.
142. Gopalsamy, A.; Shi, M.; Golas, J.; Vogan, E.; Jacob, J.; Johnson, M.; Lee, F.; Nilakantan, R.; Petersen, R.; Svenson, K.; Chopra, R.; Tam, M. S.; Wen, Y.; Ellingboe, J.; Arndt, K.; Boschelli, F. Discovery of benzisoxazoles as potent inhibitors of chaperone heat shock protein 90. J. Med. Chem. 2008, 51, 373-375.
143. Kung, P. P.; Funk, L.; Meng, J.; Collins, M.; Zhou, J. Z.; Johnson, C. M.; Ekker, A.; Wang, J.; Mehta, P.; Yin, M. J.; Rodgers, C.; Jay, Bayman, E.; Smeal, T.; Maegley, K. A.; Gehring, M. R. Dihydroxylphenyl amides as inhibitors of the Hsp90 molecular chaperone. Bioorg. Med. Chem. Lett. 2008, 18, 6273-6278.
144. Martin, C. J.; Gaisser, S.; Challis, I. R.; Carletti, I.; Wilkinson, B.; Gregory, M.; Wilkinson, B.; Gregory, M.; Prodromou, C.; Roe, M. S.; Pearl, L. H.; Boyd, S. M.; Zhang, M. Q. Molecular characterization of macbecin as an Hsp90 inhibitor. J. Med. Chem. 2008, 51, 2853-2857.
145. Zhang, M. Q.; Gaisser, S.; Mohammad Sheehan, L. S.; Vousden, W. A.; Gaitatzis, N.; Peck, G.; Coates, N. J.; Moss, S. J.; Radzom, M.; Foster, T. A.; Sheridan, R. M.; Gregory, M. A.; Roe, M. S.; Prodromou, C.; Pearl, L.; Boyd, S. M.; Wilkinson, B.; Martin, C. J. Optimizing natural products by biosynthetic engineering: discovery of nonquinone Hsp90 inhibitors. J. Med. Chem. 2008, 51, 5494-5497.
146. Williamson, D. S.; Borgognoni, J.; Clay, A.; Daniels, Z.; Dokurno, P.; Drysdale, M. J.; Foloppe, N.; Francis, G. L.; Graham, C. J.; Howes, R.; Macias, A. T.; Murray, J. B.; Parsons, R.; Shaw, T.; Surgenor, A. E.; Terry, L.; Wang, Y.; Wood, M.; Massey, A. J. Novel adenosine-derived inhibitors of 70 kDa heat shock protein, discovered through structure-based design. J. Med. Chem. 2009, 52, 1510-1513.
147. Immormino, R. M.; 4th Metzger, L. E.; Reardon, P. N.; Dollins, D. E.; Blagg, B. S. J.; Gewirth, D. T. Different poses for ligand and chaperone in inhibitor-bound Hsp90 and GRP94: implications for paralog-specific drug design. J. Mol. Biol. 2009, 388, 1033-1042.
148. Smith, J. R.; Workman, P. Targeting the cancer chaperone HSP90, Drug Discov. Today: Ther. Strateg. 2007, 4, 219-227.
149. Barril, X.; Hubbard, R. E.; Morley, S. D. Virtual screening in structure-based drug discovery Mini Rev. Med. Chem. 2004, 4, 779-791.
150. Hajduk, P. J.; Greer, J. A decade of fragment-based drug design: strategic advances and lessons learned. Nat. Rev. Drug Discov. 2007, 6, 211-219.
151. Hubbard, R. E.; Davis, B.; Chen, I.; Drysdale, M. J. The SeeDs approach: integrating fragments into drug discovery Curr. Top. Med. Chem. 2007, 7, 1568-1581.
152. Barker, J. J.; Barker, O.; Boggio, R.; Chauhan, V.; Cheng, R. K. Y.; Corden, V.; Courtney, S. M.; Edwards, N.; Falque, V. M.; Fusar, F.; Gardiner, M.; Hamelin, E. M. N.; Hesterkamp, T.; Ichihara, O.; Jones, R. S.; Mather, O.; Mercurio, C.; Minucci, S.; Montalbetti, C. A. G. N.; Muller, A.; Patel, D.; Phillips, B. G.; Varasi, M.; Whittaker, M.; Winkler, D.; Yarnold, C. J. Fragment-based identification of Hsp90 inhibitors. ChemMedChem 2009, 4, 963-966.
153. Brough, P.A.; Barril, X.; Borgognoni, J.; Chene, P.; Davies, N.G.; Davis, B.; Drysdale, M.J.; Dymock, B.; Eccles, S.A.; Garcia-Echeverria, C.; Fromont, C.; Hayes, A.; Hubbard, R.E.; Jordan, A.M.; Jensen, M.R.; Massey, A.; Merrett, A.; Padfield, A.; Parsons, R.; Radimerski, T.; Raynaud, F.I.; Robertson, A.; Roughley, S.D.; Schoepfer, J.; Simmonite, H.; Sharp, S.Y.; Surgenor, A.; Valenti, M.; Walls, S.; Webb, P.; Wood, M.; Workman, P.; Wright, L. Combining hit identification strategies: fragment-based and in silico approaches to orally active 2-aminothieno[2,3-d]pyrimidine Inhibitors of the Hsp90 Molecular Chaperone. J. Med. Chem. 2009, 52(15), 4794-4809.
154. Knox, A. J. S.; Price, T.; Pawlak, M.; Golfis, G.; Flood, C. T.; Fayne, D.; Williams, D. C.; Meegan, M. J.; Lloyd, D. G. Integration of ligand and structure-based virtual screening for the identification of the first dual targeting agent for heat shock protein 90 (Hsp90) and tubulin. J. Med. Chem. 2009, 52, 2177-2180.
155. Hong, T. J.; Park, H.; Kim, Y. J.; Jeong, J. H.; Hahn, J. S. Identification of new Hsp90 inhibitors by structure-based virtual screening. Bioorg. Med. Chem. Lett. 2009, 19, 4839-4842.
156. Barta, T. E.; Veal, J. M.; Rice, J. W.; Partridge, J. M.; Fadden, P. R.; Ma, W.; Jenks, M.; Geng, L.; Hanson, G. J.; Huang, K. H.; Barabasz, A. F.; Foley, B. E.; Otto, J.; Hall, S. E. Discovery of benzamide tetrahydro-4H- carbazol-4-ones as novel small molecule inhibitors of Hsp90. Bioorg. Med. Chem. Lett. 2008, 18, 3517-3521.
157. Huang, K. H.; Veal, J. M.; Fadden, R. P.; Rice, J. W.; Eaves, J.; Strachan, J. P.; Barabasz, A. F.; Foley, B. E.; Barta, T. E.; Ma, W.; Silinski, M. A.; Hu, M.; Partridge, J. M.; Scott, A.; Dubois, L. G.; Freed, T.; Steed, P. M.; Ommen, A. J.; Smith, E. D.; Hughes, P. F.; Woodward, A. R.; Hanson, G. J.; Mccall, W. S.; Markworth, C. J.; Hinkley, L.; Jenks, M.; Geng, L.; Lewis, M.; Otto, J.; Pronk, B.; Verleysen, K.; Hall, S. E. Discovery of novel 2-aminobenzamide inhibitors of heat shock protein 90 as potent, selective and orally active antitumor agents. J. Med. Chem. 2009, 52, 4288-4305.
158. Spichty, M.; Taly, A.; Hagn, F.; Kessler, H.; Barluenga, S.; Winssinger, N.; Karplus, M. The HSP90 binding mode of a radicicol-like E-oxime determined by docking, binding free energy estimations, and NMR 15N chemical shifts. Biophys. Chem. 2009, 143, 111-23.
159. Lauria, A.; Ippolito, M.; Almerico, A. M. Inside the Hsp90 inhibitors binding mode through induced fit docking. J. Mol. Graph. Model. 2009, 27, 712-722.
160. Lauria, A.; Ippolito, M.; Almerico, A.M. Principal component analysis on molecular descriptors as an alternative point of view in the search of new Hsp90 inhibitors. Comput. Biol. Chem. 2009, July 23, [Epub ahead of print]
161. Liu, T.; Lin, Y.; Wen, X.; Jorissen, R. N.; Gilson, M. K. BindingDB: a web-accessible database of experimentally determined protein-ligand binding affinities. Nucleic Acids Res. 2007, 35, D198-D201.
162. Solit, D. B.; Chiosis. G. Development and application of Hsp90 inhibitors. Drug Discov. Today 2008, 13, 38-43.
163. Taldone, T.; Gozman, A.; Maharaj, R.; Chiosis, G.Targeting Hsp90: small molecule inhibitors and their clinical development Curr. Opin. Pharmacol. 2008, 8, 370-374.
164. Sgobba M, Rastelli G. Structure-based and in silico design of Hsp90 inhibitors. ChemMedChem 2009, 4(9), 1399-1409.
165. Fortugno, P.; Beltrami, E.; Plescia, J.; Fontana, J.; Pradhan, D.; Marchisio, P.C.; Sessa, W. C.; Altieri, D. C. Regulation of survivin function by Hsp90. Proc. Natl. Acad. Sci. USA 2003, 100, 13791-13796.
166. Salvesen, G. S.; Duckett, C. S. Nat Rev IAP proteins: blocking the road to death's door. Mol. Cell Biol. 2002, 3, 401-410.
167. Altieri, D. C. Validating survivin as a cancer therapeutic target. Nat. Rev. Cancer 2003, 3, 46-54.
168. Carter, B. Z.; Wang, R. Y.; Schober, W. D.; Milella, M.; Chism, D.; Andreeff, M.; Targeting survivin expression induces cell proliferation defect and subsequent cell death involving mitochondrial pathway in myeloid leukemic cells. Cell Cycle 2003, 2, 488-493.
169. Sugahara, K.; Uemura, A.; Harasawa, H.; Nagai, H.; Hirakata, Y.; Tomonaga, M.; Murata, K.; Sohda, H.; Nakagoe, T.; Shibasaki, S. I.; Yamada, Y.; Kamihira, S. Clinical relevance of survivin as a biomarker in neoplasms, especially in adult T-cell leukemias and acute leukemias. Int. J. Hematol. 2004, 80, 52-58.
170. Paydas, S.; Tanriverdi, K.; Yavuz, S.; Disel, U.; Sahin, B.; Burgut, R. Survivin and aven: two distinct antiapoptotic signals in acute leukemias. Ann. Oncol. 2003, 14, 1045-1050.
171. Badran, A.; Yoshida, A.; Wano, Y.; Mutoh, M.; Imamura, S.; Yamashita, T.; Tsutani, H.; Inuzuka, M.; Ueda, T. Expression of the anti-apoptotic gene survivin in myelodysplastic syndrome. Int. J. Oncol. 2003, 22, 59-64.
172. Yamamoto, K.; Abe, S.; Nakagawa, Y.; Suzuki, K.; Hasegawa, M.; Inoue, M.; Kurata, M.; Hirokawa, K.; Kitagawa, M. Expression of IAP family proteins in myelodysplastic syndromes transforming to overt leukemia. Leukoc. Res. 2004, 28, 1203-1211.
173. Plescia, J.; Salz, W.; Xia, F.; Pennati, M.; Zaffaroni, N.; Daidone, M. G.; Meli, M.; Dohi, T.; Fortugno, P.; Nefedova, Y.; Gabrilovich, D. I.; Colombo, G.; Altieri, D.C. Rational design of shepherdin, a novel anticancer agent. Cancer Cell 2005, 7, 457-468.
174. Gyurkocza, B.; Plescia, J.; Raskett, C. M.; Garlick, D. S.; Lowry, P. A.; Carter, B. Z.; Andreeff, M.; Meli, M.; Colombo, G.; Altieri, D. C. Antileukemic activity of shepherdin and molecular diversity of hsp90 inhibitors. J. Natl. Cancer Inst. 2006, 98, 1068-1077.
175. Meli, M.; Pennati, M.; Curto, M.; Daidone, M. G.; Plescia, J.; Toba, S.; Altieri, D. C.; Zaffaroni, N.; Colombo, G. Small-molecule targeting of heat shock protein 90 chaperone function: rational identification of a new anticancer lead. J. Med. Chem. 2006, 49, 7721-7730.
176. Hieronymus, H.; Lamb, J.; Ross, K. N.; Peng, X. P.; Clement, C.; Rodina, A.; Nieto, M.; Du, J.; Stegmaier, K.; Raj, S. M.; Maloney, K. N.; Clardy, J.; Hahn, W. C.; Chiosis, G.; Golub, T. R. Gene expression signature-based chemical genomic prediction identifies a novel class of HSP90 pathway modulators. Cancer Cell 2006, 10, 321-330.
177. Zhang, T.; Hamza, A.; Cao, X.; Wang, B.; Yu, S.; Zhan, C. G.; Sun, D. A novel Hsp90 inhibitor to disrupt Hsp90/Cdc37 complex against pancreatic cancer cells. Mol. Cancer Ther. 2008, 7, 162-170.
178. Brandt, G. E. L.; Schmidt, M. D.; Prisinzano, T. E.; Blagg, B. S. J. Gedunin, a novel hsp90 inhibitor: semisynthesis of derivatives and preliminary structure-activity relationships. J. Med. Chem. 2008, 51, 6495-6502.
179. Marcu, M. G.; Schulte, T. W.; Neckers, L. Novobiocin and related coumarins and depletion of heat shock protein 90-dependent signaling proteins. J. Natl. Cancer Inst. 2000, 92, 242-248.
180. Marcu, M. G.; Chadli, A.; Bouhouche, I.; Catelli, M.; Neckers, L. M. The heat shock protein 90 antagonist novobiocin interacts with a previously unrecognized ATP-binding domain in the carboxyl terminus of the chaperone. J. Biol. Chem. 2000, 275, 37181-37186.
181. Garnier, C.; Lafitte, D.; Tsvetkov, P. O.; Barbier, P.; Devin, J. L.; Millot, J. M.; Briand, C.; Makarov, A. A.; Catelli, M. G.; Peyrot, V. Binding of ATP to heat shock protein 90: evidence for an ATPbinding site in the C-terminal domain. J. Biol. Chem. 2002, 277, 12208-12214.
182. Soti, C.; Racz, A.; Csermely, P. A Nucleotide-dependent molecular switch controls ATP binding at the C-terminal domain of Hsp90. N-terminal nucleotide binding unmasks a C-terminal binding pocket J. Biol. Chem. 2002, 277, 7066-7075.
183. Soti, C.; Vermes, A.; Haystead, T. A. J.; Csermely, P. Comparative analysis of the ATP-binding sites of Hsp90 by nucleotide affinity cleavage: a distinct nucleotide specificity of the C-terminal ATPbinding site. Eur. J. Biochem. 2003, 270, 2421-2428.
184. Yu, X. M.; Shen, G.; Neckers, L.; Blake, H.; Holzbeierlein, J.; Cronk, B.; Blagg, B. S. J. Hsp90 inhibitors identified from a library of novobiocin analogues. J. Am. Chem. Soc 2005, 127, 12778-12779.
185. Allan, R. K.; Mok, D.; Ward, B. K.; Ratajczak, T. Modulation of chaperone function and cochaperone interaction by novobiocin in the C-terminal domain of Hsp90: evidence that coumarin antibiotics disrupt Hsp90 dimerization. J. Biol. Chem. 2006, 281, 7161-7171.
186. Burlison, J. A.; Neckers, L.; Smith, A. B.; Maxwell, A.; Blagg, B. S. J. Novobiocin: redesigning a DNA gyrase inhibitor for selective inhibition of Hsp90. J. Am. Chem. Soc. 2006, 128, 15529-15536.
187. Huang, Y. T.; Blagg, B. S. J. A library of noviosylated coumarin analogues. J. Org. Chem. 2007, 72, 3609-3613.
188. Le Bras, G.; Radanyi, C.; Peyrat, J. F.; Brion, J. D.; Alami, M.; Marsaud, V.; Stella, B.; Renoir, J. M. New novobiocin analogues as antiproliferative agents in breast cancer cells and potential inhibitors of heat shock protein 90. J. Med. Chem. 2007, 50, 6189-6200.
189. Donnelly, A. C.; Mays, J. R.; Burlison, J. A.; Nelson, J. T.; Vielhauer, G.; Holzbeierlein, J.; Blagg, B. S. J. The design, synthesis, and evaluation of coumarin ring derivatives of the novobiocin scaffold that exhibit antiproliferative activity. J. Org. Chem. 2008, 73, 8901-8920.
190. Burlison, J. A.; Avila, C.; Vielhauer, G.; Lubbers, D. J.; Holzbeierlein, J.; Blagg, B. S. J. Development of novobiocin analogues that manifest anti-proliferative activity against several cancer cell lines. J. Org. Chem. 2008, 73, 2130-2137.
191. Donnelly, A.; Blagg, B. S. J. Novobiocin and additional inhibitors of the Hsp90 C-terminal nucleotide-binding pocket. Curr. Med. Chem. 2008, 15, 2702-2717.
192. Cox, M. B.; Miller CA 3rd. Pharmacological and genetic analysis of 90-kDa heat shock isoprotein-aryl hydrocarbon receptor complexes. Mol. Pharmacol. 2003, 64, 1549-1556.
193. Sgobba, M.; Degliesposti, G.; Ferrari, A. M.; Rastelli, G. Structural models and binding site prediction of the C-terminal domain of human Hsp90: a new target for anticancer drugs. Chem. Biol. Drug Des. 2008, 71, 420-433.
194. Wang, S.; Pashtan, I.; Tsutsumi, S.; Xu, W.; Neckers, L. Cancer cells harboring MET gene amplification activate alternative signaling pathways to escape MET inhibition but remain sensitive to Hsp90 inhibitors. Cell Cycle 2009, 8, 2050-2056.
195. Hwang, M.; Moretti, L.; Lu, B. HSP90 inhibitors: multi-targeted antitumor effects and novel combinatorial therapeutic approaches in cancer therapy. Curr. Med. Chem. 2009, 16, 3081-3092.
196. Rice, J. W.; Veal, J. M.; Fadden, R. P.; Barabasz, A. F.; Partridge, J. M.; Barta, T. E.; Dubois, L. G.; Huang, K. H.; Mabbett, S. R.; Silinski, M. A.; Steed, P. M.; Hall, S. E. Mabbett, S. R.; Silinski, M. A.; Steed, P. M.; Hall, S. E. Small molecule inhibitors of Hsp90 potently affect inflammatory disease pathways and exhibit activity in models of rheumatoid arthritis. Arthritis Rheum. 2008, 58, 3765-3775.
197. Kang, B. H.; Plescia, J.; Song, H. Y.; Meli, M.; Colombo, G.; Beebe, K.; Scroggins, B.; Neckers, L.; Altieri, D. C. Combinatorial drug design targeting multiple cancer signaling networks controlled by mitochondrial Hsp90. J. Clin. Invest. 2009, 119, 454-464.